Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis

Documenti analoghi

• Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology
  di: Wheaton, Lorna, et al.
  Pubblicazione: (2024)
• Methods of multi-indication meta-analysis for health technology assessment: a simulation study
  di: Glynn, David, et al.
  Pubblicazione: (2025)
• Meta-analysis and network meta-analysis of time-to-event outcomes with non-proportional hazards: a Bayesian time-varying hazard ratio approach
  di: Owen, Rhiannon K, et al.
  Pubblicazione: (2026)
• Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
  di: Ronald C. Petersen, et al.
  Pubblicazione: (2025)
• What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?
  di: Orestes Vicente Forlenza
  Pubblicazione: (2025)